Clinical Physiology of Circulation

ISSN 1814-6910 (Print)
ISSN 2410-9134 (Online)

 

Chief Editor

Leo A. Bockeria, MD, PhD, DSc, Professor, Academician of Russian Academy of Sciences, President of Bakoulev National Medical Research Center for Cardiovascular Surgery


Issue's catalogue ➤ КФК. 2024; 21 (4): 273-368 ➤ Формирование сердечно-сосудистых нарушений при болезни Паркинсона

Formation of cardiovascular disorders in Parkinson’s disease

Authors: Mamalyga M.L.

Link: Clinical Physiology of Blood Circulaiton. 2024; 21 (4): 311-322

Download
Full text:  

References

  1. Cuenca L., Almela P., Navarro-Zaragoza J., Fernandez V.E., Gonzalez-Cuello A., Laorden L. et al. Cardiac changes in Parkinson’s disease: lessons from clinical and experimental evidence. Int. J. Mol. Sci. 2021; 226: 13488–13497. DOI: 10.3390/ijms222413488
  2. Scorza F.A., Carmo A.C., Fiorini A.C., Nejm M.B., Scorza C.A., Finsterer J. et al. Sudden unexpected death in Parkinson’s disease (SUDPAR): a review of publications since the decade of the brain. Clinics. 2017; 72: 649–651. DOI: 10.6061/clinics/2017(11)01
  3. Симоненко В.Б., Широков Е.А. Превентивная кардионеврология. СПб.: Медицина; 2008.
  4. Biso S., Wongrakpanich S., Agrawal A., Yadlapati S., Kishlyansky M., Figueredo V.A. Review of neurogenic stunned myocardium. Cardiovasc. Psych. Neurol. 2017; 2017 (1): 5842182. DOI: 10.1155/2017/5842182
  5. Голухова Е.З. Отчет о научной и лечебной работе Национального медицинского исследовательского центра сердечно-сосудистой хирургии им. А.Н. Бакулева Минздрава России за 2023 год и перспективы развития. Сердечно-сосудистые заболевания. Бюллетень НЦССХ им. А.Н. Бакулева РАМН. 2024; 25 (Спецвыпуск): 5–141. DOI: 10.24022/1810-0694-2024-25S
  6. Mamalyga M.L. Influence of pre-symptomatic and symptomatic stages of Parkinson’s disease and its treatment upon changes of variability of cardiac rhythm. Roman. J. Neurol. 2017; 16 (1): 9–14. DOI: 10.37897/RJN.2017.1.2
  7. Goldstein D.S., Holmes C., Li S.T., Bruce S., Metman L.V., Cannon R.O. Cardiac sympathetic denervation in Parkinson disease. Ann. Intern. Med. 2000; 133 (5): 338–345. DOI: 10.7326/0003-4819-133-5-200009050-00009
  8. Мамалыга М.Л. Циркадные изменения структуры сердечного ритма при досимптомной и симптомной стадиях болезни Паркинсона. Журнал неврологии и психиатрии им. С.С. Корсакова. 2018; 118 (9): 77–83. DOI: 10.17116/jnevro201811808185
  9. Бузиашвили Ю.И., Асымбекова Э.У., Иошина В.И., Кокшенева И.В. Результаты лечебной и научной работы клинико-диагностического отделения Национального медицинского исследовательского центра сердечно-сосудистой хирургии им. А.Н. Бакулева Минздрава России за 2020 год. Сердечно-сосудистые заболевания. Бюллетень НЦССХ им. А.Н. Бакулева РАМН. 2022; 23 (1): 120–129. DOI: 10.24022/1810-0694-2022-23-1-120-129
  10. Deguchi K., Sasaki I., Tsukaguchi M., Kamoda M., Touge T., Takeuchi H. et al. Abnormalities of rate-corrected QT intervals in Parkinson’s disease – a comparison with multiple system atrophy and progressive supranuclear palsy. J. Neurol. Sci. 2002; 199: 31–37. DOI: 10.1016/s0022-510x(02)00079-5
  11. Убушиев С.Д., Шогенов М.А., Дарвиш Н.А., Румянцев Л.Н. Успешная симультанная реваскуляризация миокарда и головного мозга у пациентки пожилого возраста. Сердечно-сосудистые заболевания. Бюллетень НЦССХ им. А.Н. Бакулева РАМН. 2022; 23 (2): 248–254. DOI: 10.24022/1810-0694-2022-23-2-248-254
  12. Mamalyga M.L. Cardiovascular dysfunctions in brain disorders and their treatment. Germany: Academic Publishing; 2017.
  13. Dickson D.W. Neuropathology of Parkinson disease. Park. Relat. Disord. 2018; 46: 30–33. DOI: 10.1016/j.parkreldis.2017.07.033
  14. Xu T., Dong W., Liu J., Yin P., Wang Z., Zhang L. et al. Disease burden of Parkinson’s disease in China and its provinces from 1990 to 2021: fndings from the global burden of disease study. Lancet Region. Health-West. Pac. 2024; 46: 101078. DOI: 10.1016/j.lanwpc.2024.101078
  15. Tysnes O.B., Storstein A. Epidemiology of Parkinson’s disease. J. Neural Transm. 2017; 124 (8): 901–905. DOI: 10.1007/s00702-017-1686-y
  16. Reeve A., Simcox E., Turnbull D. Ageing and Parkinson’s disease: why is advancing age the biggest risk factor? Ageing. Res. Rev. 2014; 14 (100): 19–30. DOI: 10.1016/j.arr.2014.01.004
  17. Fall P., Saleh A., Fredrickson M., Olsson J.E., Granérus A.K. Survival time, mortality, and cause of death in elderly patients with Parkinson’s disease: a 9-year follow-up. Mov. Disord. 2003; 18 (11): 1312–1316. DOI: 10.1002/mds.10537
  18. Nataraj A., Rajput A.H. Parkinson’s disease, stroke, and related epidemiology. Mov. Disord. 2005; 20 (11): 1476–1480. DOI: 10.1002/mds.20608
  19. Korten A., Lodder J., Vreeling F., Boreas A., Raak L., Kessels F. Stroke and idiopathic Parkinson’s disease: does a shortage of dopamine ofer protection against stroke? Mov. Disord. 2001; 16 (1): 119–123. DOI: 10.1002/1531-8257(200101)16:1<119::aid-mds1024>3.0.co;2-w
  20. Bodenmann P., Ghika J., Van Melle G., Bogousslavsky J. Neurological comorbidity in parkinsonism. Revue Neurol. 2001; 157 (1): 45–54.
  21. Piqueras-Flores J., López-García A., Moreno-Reig Á., GonzálezMartínez A., Hernández-González A., Vaamonde-Gamo J. et al. Structural and functional alterations of the heart in Parkinson’s disease. Neurol. Res. 2017; 40 (1): 53–61. DOI: 10.1080/01616412.2017.1390933
  22. Park J.H., Kim D.H., Park Y.G., Kwon D.Y., Choi M., Jung J.H. et al. Association of Parkinson disease with risk of cardiovascular disease and all-cause mortality: a nationwide, population-based cohort study. Circulation. 2020; 141 (14): 1205–1207. DOI: 10.1161/circulationaha.119.044948
  23. Iwanaga K., Wakabayashi K., Yoshimoto M., Tomita I., Satoh H., Takashima H. et al. Lewy body-type degeneration in cardiac plexus in Parkinson’s and incidental Lewy body diseases. Neurology. 1999; 52 (6): 1269–1271. DOI: 10.1212/WNL.52.6.1269
  24. Ke J.Q., Shao S.M., Zheng Y.Y., Fu F.W., Zheng G.Q., Liu C.F. Sympathetic skin response and heart rate variability in predicting autonomic disorders in patients with Parkinson disease. Med. (United States). 2017; 96 (18): e6523. DOI: 10.1097/MD.0000000000006523
  25. Courbon F., Brefel-Courbon C., Thalamas C., Alibelli M.J., Berry I., Montastruc J. L. et al. Cardiac MIBG scintigraphy is a sensitive tool for detecting cardiac sympathetic denervation in Parkinson’s disease. Mov. Disord. 2003; 18 (8): 890–897. DOI: 10.1002/mds.10461
  26. Hughes T.A., Ross H.F., Mindham R.H., Spokes E.G. Mortality in Parkinson’s disease and its association with dementia and depression. Acta. Neuro.l Scand. 2004; 110 (2): 118–123. DOI: 10.1111/j.1600-0404.2004.00292.x
  27. Hoogland J., Post B., Bie R.M.A. Overall and disease related mortality in Parkinson’s disease – a longitudinal cohort study. J. Parkinsons Dis. 2019; 9 (4): 767–774. DOI: 10.3233/JPD-191652
  28. Xu S., Li W., Di Q. Association of dietary patterns with Parkinson’s disease: a cross-sectional study based on the United States National Health and Nutritional. Examination Survey Database. Eur. Neurol. 2023; 86 (1): 63–72. DOI: 10.1159/000527537
  29. Velseboer D.C., Haan R.J., Wieling W., Goldstein D.S., Bie R.M.A. Prevalence of orthostatic hypotension in Parkinson’s disease: a systematic review and meta-analysis. Parkinsonism Relat. Disord. 2011; 17 (10): 724–729. DOI: 10.1016/j.parkreldis.2011.04.016
  30. Palma J.A., Gomez-Esteban J.C., Norcliffe-Kaufmann L., Martinez J., Tijero B., Berganzo K. et al. Orthostatic hypotension in Parkinson disease: how much you fall or how low you go? Mov. Disord. 2015; 30 (5): 639–645. DOI: 10.1002/mds.26079
  31. Eigenbrodt M.L., Rose K.M., Couper D.J., Arnett D.K., Smith R., Jones D. Orthostatic hypotension as a risk factor for stroke: the atherosclerosis risk in communities (ARIC) study, 1987–1996. Stroke. 2000; 31 (10): 2307–2313. DOI: 10.1161/01.STR.31.10.2307
  32. Fedorowski A., Stavenow L., Hedblad B., Berglund G., Nilsson P.M., Melander O. Orthostatic hypotension predicts all-cause mortality and coronary events in middleaged individuals (The Malmo Preventive Project). Eur. Heart J. 2010; 31 (1): 85–91. DOI: 10.1093/eurheartj/ehp329
  33. Mol A., Bui Hoang P.T.S., Sharmin S., Reijnierse E.M., Wezel R.J.A., Meskers C.G.M. et al. Orthostatic hypotension and falls in older adults: a systematic review and meta-analysis. J. Am. Med. Dir. Assoc. 2019; 20 (5): 589–597. DOI: 10.1016/j.jamda.2018.11.003
  34. Rong S., Xu G., Liu B., Sun Y., Snetselaar L.G., Wallace R.B. et al. Trends in mortality from Parkinson disease in the United States, 1999– 2019. Neurology. 2021; 97 (20): 1986–1993. DOI: 10.1212/WNL.0000000000012826
  35. Guo J.D., Zhao X., Li Y., Li G.R., Liu X.L. Damage to dopaminergic neurons by oxidative stress in Parkinson’s disease. Int. J. Mol. Med. 2018; 41 (4): 1817–1825. DOI: 10.3892/ijmm.2018.3406
  36. Kander M.C., Cui Y., Liu Z. Gender difference in oxidative stress: a new look at the mechanisms for cardiovascular diseases. J. Cell. Mol. Med. 2017; 21 (5): 1024–1032. DOI: 10.1111/jcmm.13038
  37. Patel R., Kompoliti K. Sex and gender differences in Parkinson’s disease. Neurologic Clinics. 2023; 41 (2): 371–379. DOI: 10.1136/jnnp.2006.103788
  38. Subramaniam S.R., Chesselet M.F. Mitochondrial dysfunction and oxidative stress in Parkinson’s disease. Progr. Neurobiol. 2013; 106: 17–32. DOI: 10.1016/j.pneurobio.2013.04.004
  39. Wei Z., Li X., Li X., Liu Q., Cheng Y. Oxidative stress in Parkinson’s disease: a systematic review and meta-analysis. Front. Molecul. Neurosc. 2018; 11: 236–242. DOI: 10.3389/fnmol.2018.00236
  40. Chang K.H., Chen C.M. The Role of oxidative stress in Parkinson’s disease. Antioxidants. 2020; 9 (7): 597–602. DOI: 10.5607/en.2013.22.1.11
  41. Dorszewska J., Kowalsk M., Prendeck M., Pieku T., Kozłowsk J. Oxidative stress factors in Parkinson’s disease. Neural. Regener. Res. 2021; 169 (7): 1383–1391. DOI: 10.4103/1673-5374.300980
  42. Nakanishi T., Iwata M., Goto I., Kanazawa I., Kowa H., Mannen T. et al. Nation-wide collaborative study on the long-term effects of bromocriptine in the treatment of parkinsonian patients. Eur. Neurol. 1991; 32 (1): 9–22. DOI: 10.1159/000116865
  43. Cheung D., Heaney A. Dopamine agonists and valvular heart disease. Curr. Opin. Endocrinol. Diabetes. Obes. 2009; 16 (4): 316–320. DOI: 10.1097/MED.0b013e32832d9f64
  44. Mokhles M.M., Trifirò G., Dieleman J.P., Haag M.D., Soest E.M., Verhamme K. M. et al. The risk of new onset heart failure associated with dopamine agonist use in Parkinson’s disease. Pharmacol. Res. 2012; 65 (3): 358–364. DOI: 10.1016/j.phrs.2011.11.009
  45. Gu H., Luck S., Carroll P.V., Powrie J., Chambers J. Cardiac valve disease and low‐dose dopamine agonist therapy: an artefact of reporting bias? Clin. Endocrinol. 2011; 74 (5): 608–612. DOI: 10.1111/j.1365-2265.2010.03973.x
  46. Schade R., Andersohn F., Suissa S., Haverkamp W., Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N. Engl. J. Med. 2007; 356 (1): 29–38. DOI: 10.1056/NEJMoa062222
  47. Zanettini R., Antonini A., Gatto G., Gentile R., Tesei S., Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. N. Engl. J. Med. 2007; 356 (1): 39–46. DOI: 10.1056/NEJMoa054830
  48. Goldberg E., Grau J.B., Fortier J.H., Salvati E., Levy R.J., Ferrari G. Serotonin and catecholamines in the development and progression of heart valve diseases. Cardiovasc. Res. 2017; 113 (8): 849–857. DOI: 10.1093/cvr/cvx092
  49. Lee Y.C., Lin C.H., Wu R.M., Lin M.S., Lin J.W., Chang C.H. et al. Discontinuation of statin therapy associates with Parkinson disease: a population-based study. Neurology. 2013; 81 (5): 410–416. DOI: 10.1212/WNL.0b013e31829d873c
  50. Lang Y., Gong D., Fan Y. Calcium channel blocker use and risk of Parkinson’s disease: a meta-analysis. Pharmacoepidemiol. Drug. Saf. 2015; 24 (6): 559–566. DOI: 10.1002/pds.3781
  51. Sheng Z., Jia X., Kang M. Statin use and risk of Parkinson’s disease: a meta-analysis. Behav. Brain.Res. 2016; 309: 29–34. DOI: 10.1016/j.bbr.2016.04.046
  52. Babar B.A., Kettunen R., Tiihonen M., Hartikainen S., Tolppanen A.M. Prevalence of cardiovascular drugs and oral anticoagulant use among persons with and without Parkinson’s disease. Cardiology. 2024; 149 (2): 127–136. DOI: 10.1159/000535691
  53. Rivasi G., Rafanelli M., Mossello E., Brignole M., Ungar A. Drug-related orthostatic hypotension: beyond anti-hypertensive medications. Drugs. Aging. 2020; 37 (10): 725–738. DOI: 10.1007/s40266-020-00796-5
  54. Wojtala J., Heber I.A., Neuser P., Heller J., Kalbe E., Rehberg S.P. et al. Cognitive decline in Parkinson’s disease: the impact of the motor phenotype on cognition. J. Neurol. Neurosurg. Psychiatry. 2019; 90 (2): 171–179. DOI: 10.1136/jnnp-2018-319008
  55. Mehrpouya M., Ataei S., Nili-Ahmadabadi A. Potential drug interactions with cholinesterase inhibitors in alzheimer patients: a guideline for neurologists. J. Appl. Pharm. Sci. 2017; 7 (1): 223–230. DOI: 10.7324/JAPS.2017.70134
  56. Chaumont M., Pourcelet A., Nuffelen M., Racapé J., Leeman M., Hougardy J.M. Acute kidney injury in elderly patients with chronic kidney disease: do angiotensin-converting enzyme inhibitors carry a risk? J. Clin. Hypertens. 2016; 18 (6): 514–521. DOI: 10.1111/jch.12795
  57. Lertxundi U., Domingo-Echaburu S., Soraluce A., García M., Ruiz-Osante B., Aguirre C. Domperidone in Parkinson’s disease: a perilous arrhythmogenic or the gold standard? Curr. Drug. Saf. 2013; 8: 63–68. DOI: 10.2174/1574886311308010009
  58. Simeonova M., Vries F., Pouwels S., Driessen J.H., Leufkens H.G., Cadarette S.M. et al. Increased risk of all‐cause mortality associated with domperidone use in Parkinson’s patients: a population‐based cohort study in the UK. Br. J. Clin. Pharmacol. 2018; 84 (11): 2551–2561. DOI: 10.1111/bcp.13708
  59. Günaydın Z.Y., Özer F.F., Karagöz A., Bektaş O., Karataş M.B., Vural A. et al. Evaluation of cardiovascular risk in patients with Parkinson disease under levodopa treatment. J. Geriatr. Cardiol. 2016; 13 (1): 75–80. DOI: 10.11909/j.issn.1671-5411.2016.01.003
****
  1. Cuenca L., Almela P., Navarro-Zaragoza J., Fernandez V.E., Gonzalez-Cuello A., Laorden L. et al. Cardiac changes in Parkinson’s disease: lessons from clinical and experimental evidence. Int. J. Mol. Sci. 2021; 226: 13488–13497. DOI: 10.3390/ijms222413488
  2. Scorza F.A., Carmo A.C., Fiorini A.C., Nejm M.B., Scorza C.A., Finsterer J. et al. Sudden unexpected death in Parkinson’s disease (SUDPAR): a review of publications since the decade of the brain. Clinics. 2017; 72: 649–651. DOI: 10.6061/clinics/2017(11)01
  3. Simonenko V.B., Shirokov E.A. Preventive cardioneurology. St. Petersburg; 2008 (in Russ.).
  4. Biso S., Wongrakpanich S., Agrawal A., Yadlapati S., Kishlyansky M., Figueredo V.A. Review of neurogenic stunned myocardium. Cardiovasc. Psych. Neurol. 2017; 2017 (1): 5842182. DOI: 10.1155/2017/5842182
  5. Golukhova E.Z. Report on the scientific and clinical activity of Bakoulev National Medical Research Center for Cardiovascular Surgery for 2023 and development prospects. The Bulletin of Bakoulev Center. Cardiovascular Diseases. 2024; 25 (Special Issue): 5–141 (in Russ). DOI: 10.24022/1810-0694-2024-25S
  6. Mamalyga M.L. Influence of pre-symptomatic and symptomatic stages of Parkinson’s disease and its treatment upon changes of variability of cardiac rhythm. Roman. J. Neurol. 2017; 16 (1): 9–14. DOI: 10.37897/RJN.2017.1.2
  7. Goldstein D.S., Holmes C., Li S.T., Bruce S., Metman L.V., Cannon R.O. Cardiac sympathetic denervation in Parkinson disease. Ann. Intern. Med. 2000; 133 (5): 338–345. DOI: 10.7326/0003-4819-133-5-200009050-00009
  8. Mamalyga M.L. Circadian changes in the structure of cardiac rhythm during pre-symptomatic and symptomatic stages of Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2018; 118 (9): 77–83 (in Russ.). DOI: 10.17116/jnevro201811808185
  9. Buziashvili Yu.I., Asymbekova E.U., Ioshina V.I., Koksheneva I.V. The results of the medical and scientific work of the Clinical-Diagnostic Department of Bakoulev National Medical Research Center for Cardiovascular Surgery for 2020. The Bulletin of Bakoulev Center. Cardiovascular Diseases. 2022; 23 (1): 120–129 (in Russ). DOI: 10.24022/1810-0694-2022-23-1-120-129
  10. Deguchi K., Sasaki I., Tsukaguchi M., Kamoda M., Touge T., Takeuchi H. et al. Abnormalities of rate-corrected QT intervals in Parkinson’s disease – a comparison with multiple system atrophy and progressive supranuclear palsy. J. Neurol. Sci. 2002; 199: 31–37. DOI: 10.1016/s0022-510x(02)00079-5
  11. Ubushiev S.D., Shogenov M.A., Darvish N.A., Rumyantsev L.N. Successful myocardial and brain revascularization in an elderly patient. The Bulletin of Bakoulev Center. Cardiovascular Diseases. 2022; 23 (2): 248–254 (in Russ.). DOI: 10.24022/1810-0694-2022-23-2-248-254
  12. Mamalyga M.L. Cardiovascular dysfunctions in brain disorders and their treatment. Germany: Academic Publishing; 2017.
  13. Dickson D.W. Neuropathology of Parkinson disease. Park. Relat. Disord. 2018; 46: 30–33. DOI: 10.1016/j.parkreldis.2017.07.033
  14. Xu T., Dong W., Liu J., Yin P., Wang Z., Zhang L. et al. Disease burden of Parkinson’s disease in China and its provinces from 1990 to 2021: fndings from the global burden of disease study. Lancet Region. Health-West. Pac. 2024; 46: 101078. DOI: 10.1016/j.lanwpc.2024.101078
  15. Tysnes O.B., Storstein A. Epidemiology of Parkinson’s disease. J. Neural Transm. 2017; 124 (8): 901–905. DOI: 10.1007/s00702-017-1686-y
  16. Reeve A., Simcox E., Turnbull D. Ageing and Parkinson’s disease: why is advancing age the biggest risk factor? Ageing. Res. Rev. 2014; 14 (100): 19–30. DOI: 10.1016/j.arr.2014.01.004
  17. Fall P., Saleh A., Fredrickson M., Olsson J.E., Granérus A.K. Survival time, mortality, and cause of death in elderly patients with Parkinson’s disease: a 9-year follow-up. Mov. Disord. 2003; 18 (11): 1312–1316. DOI: 10.1002/mds.10537
  18. Nataraj A., Rajput A.H. Parkinson’s disease, stroke, and related epidemiology. Mov. Disord. 2005; 20 (11): 1476–1480. DOI: 10.1002/mds.20608
  19. Korten A., Lodder J., Vreeling F., Boreas A., Raak L., Kessels F. Stroke and idiopathic Parkinson’s disease: does a shortage of dopamine ofer protection against stroke? Mov. Disord. 2001; 16 (1): 119–123. DOI: 10.1002/1531-8257(200101)16:1<119::aid-mds1024>3.0.co;2-w
  20. Bodenmann P., Ghika J., Van Melle G., Bogousslavsky J. Neurological comorbidity in parkinsonism. Revue Neurol. 2001; 157 (1): 45–54.
  21. Piqueras-Flores J., López-García A., Moreno-Reig Á., GonzálezMartínez A., Hernández-González A., Vaamonde-Gamo J. et al. Structural and functional alterations of the heart in Parkinson’s disease. Neurol. Res. 2017; 40 (1): 53–61. DOI: 10.1080/01616412.2017.1390933
  22. Park J.H., Kim D.H., Park Y.G., Kwon D.Y., Choi M., Jung J.H. et al. Association of Parkinson disease with risk of cardiovascular disease and all-cause mortality: a nationwide, population-based cohort study. Circulation. 2020; 141 (14): 1205–1207. DOI: 10.1161/circulationaha.119.044948
  23. Iwanaga K., Wakabayashi K., Yoshimoto M., Tomita I., Satoh H., Takashima H. et al. Lewy body-type degeneration in cardiac plexus in Parkinson’s and incidental Lewy body diseases. Neurology. 1999; 52 (6): 1269–1271. DOI: 10.1212/WNL.52.6.1269
  24. Ke J.Q., Shao S.M., Zheng Y.Y., Fu F.W., Zheng G.Q., Liu C.F. Sympathetic skin response and heart rate variability in predicting autonomic disorders in patients with Parkinson disease. Med. (United States). 2017; 96 (18): e6523. DOI: 10.1097/MD.0000000000006523
  25. Courbon F., Brefel-Courbon C., Thalamas C., Alibelli M.J., Berry I., Montastruc J. L. et al. Cardiac MIBG scintigraphy is a sensitive tool for detecting cardiac sympathetic denervation in Parkinson’s disease. Mov. Disord. 2003; 18 (8): 890–897. DOI: 10.1002/mds.10461
  26. Hughes T.A., Ross H.F., Mindham R.H., Spokes E.G. Mortality in Parkinson’s disease and its association with dementia and depression. Acta. Neuro.l Scand. 2004; 110 (2): 118–123. DOI: 10.1111/j.1600-0404.2004.00292.x
  27. Hoogland J., Post B., Bie R.M.A. Overall and disease related mortality in Parkinson’s disease – a longitudinal cohort study. J. Parkinsons Dis. 2019; 9 (4): 767–774. DOI: 10.3233/JPD-191652
  28. Xu S., Li W., Di Q. Association of dietary patterns with Parkinson’s disease: a cross-sectional study based on the United States National Health and Nutritional. Examination Survey Database. Eur. Neurol. 2023; 86 (1): 63–72. DOI: 10.1159/000527537
  29. Velseboer D.C., Haan R.J., Wieling W., Goldstein D.S., Bie R.M.A. Prevalence of orthostatic hypotension in Parkinson’s disease: a systematic review and meta-analysis. Parkinsonism Relat. Disord. 2011; 17 (10): 724–729. DOI: 10.1016/j.parkreldis.2011.04.016
  30. Palma J.A., Gomez-Esteban J.C., Norcliffe-Kaufmann L., Martinez J., Tijero B., Berganzo K. et al. Orthostatic hypotension in Parkinson disease: how much you fall or how low you go? Mov. Disord. 2015; 30 (5): 639–645. DOI: 10.1002/mds.26079
  31. Eigenbrodt M.L., Rose K.M., Couper D.J., Arnett D.K., Smith R., Jones D. Orthostatic hypotension as a risk factor for stroke: the atherosclerosis risk in communities (ARIC) study, 1987–1996. Stroke. 2000; 31 (10): 2307–2313. DOI: 10.1161/01.STR.31.10.2307
  32. Fedorowski A., Stavenow L., Hedblad B., Berglund G., Nilsson P.M., Melander O. Orthostatic hypotension predicts all-cause mortality and coronary events in middleaged individuals (The Malmo Preventive Project). Eur. Heart J. 2010; 31 (1): 85–91. DOI: 10.1093/eurheartj/ehp329
  33. Mol A., Bui Hoang P.T.S., Sharmin S., Reijnierse E.M., Wezel R.J.A., Meskers C.G.M. et al. Orthostatic hypotension and falls in older adults: a systematic review and meta-analysis. J. Am. Med. Dir. Assoc. 2019; 20 (5): 589–597. DOI: 10.1016/j.jamda.2018.11.003
  34. Rong S., Xu G., Liu B., Sun Y., Snetselaar L.G., Wallace R.B. et al. Trends in mortality from Parkinson disease in the United States, 1999– 2019. Neurology. 2021; 97 (20): 1986–1993. DOI: 10.1212/WNL.0000000000012826
  35. Guo J.D., Zhao X., Li Y., Li G.R., Liu X.L. Damage to dopaminergic neurons by oxidative stress in Parkinson’s disease. Int. J. Mol. Med. 2018; 41 (4): 1817–1825. DOI: 10.3892/ijmm.2018.3406
  36. Kander M.C., Cui Y., Liu Z. Gender difference in oxidative stress: a new look at the mechanisms for cardiovascular diseases. J. Cell. Mol. Med. 2017; 21 (5): 1024–1032. DOI: 10.1111/jcmm.13038
  37. Patel R., Kompoliti K. Sex and gender differences in Parkinson’s disease. Neurologic Clinics. 2023; 41 (2): 371–379. DOI: 10.1136/jnnp.2006.103788
  38. Subramaniam S.R., Chesselet M.F. Mitochondrial dysfunction and oxidative stress in Parkinson’s disease. Progr. Neurobiol. 2013; 106: 17–32. DOI: 10.1016/j.pneurobio.2013.04.004
  39. Wei Z., Li X., Li X., Liu Q., Cheng Y. Oxidative stress in Parkinson’s disease: a systematic review and meta-analysis. Front. Molecul. Neurosc. 2018; 11: 236–242. DOI: 10.3389/fnmol.2018.00236
  40. Chang K.H., Chen C.M. The Role of oxidative stress in Parkinson’s disease. Antioxidants. 2020; 9 (7): 597–602. DOI: 10.5607/en.2013.22.1.11
  41. Dorszewska J., Kowalsk M., Prendeck M., Pieku T., Kozłowsk J. Oxidative stress factors in Parkinson’s disease. Neural. Regener. Res. 2021; 169 (7): 1383–1391. DOI: 10.4103/1673-5374.300980
  42. Nakanishi T., Iwata M., Goto I., Kanazawa I., Kowa H., Mannen T. et al. Nation-wide collaborative study on the long-term effects of bromocriptine in the treatment of parkinsonian patients. Eur. Neurol. 1991; 32 (1): 9–22. DOI: 10.1159/000116865
  43. Cheung D., Heaney A. Dopamine agonists and valvular heart disease. Curr. Opin. Endocrinol. Diabetes. Obes. 2009; 16 (4): 316–320. DOI: 10.1097/MED.0b013e32832d9f64
  44. Mokhles M.M., Trifirò G., Dieleman J.P., Haag M.D., Soest E.M., Verhamme K. M. et al. The risk of new onset heart failure associated with dopamine agonist use in Parkinson’s disease. Pharmacol. Res. 2012; 65 (3): 358–364. DOI: 10.1016/j.phrs.2011.11.009
  45. Gu H., Luck S., Carroll P.V., Powrie J., Chambers J. Cardiac valve disease and low‐dose dopamine agonist therapy: an artefact of reporting bias? Clin. Endocrinol. 2011; 74 (5): 608–612. DOI: 10.1111/j.1365-2265.2010.03973.x
  46. Schade R., Andersohn F., Suissa S., Haverkamp W., Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N. Engl. J. Med. 2007; 356 (1): 29–38. DOI: 10.1056/NEJMoa062222
  47. Zanettini R., Antonini A., Gatto G., Gentile R., Tesei S., Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. N. Engl. J. Med. 2007; 356 (1): 39–46. DOI: 10.1056/NEJMoa054830
  48. Goldberg E., Grau J.B., Fortier J.H., Salvati E., Levy R.J., Ferrari G. Serotonin and catecholamines in the development and progression of heart valve diseases. Cardiovasc. Res. 2017; 113 (8): 849–857. DOI: 10.1093/cvr/cvx092
  49. Lee Y.C., Lin C.H., Wu R.M., Lin M.S., Lin J.W., Chang C.H. et al. Discontinuation of statin therapy associates with Parkinson disease: a population-based study. Neurology. 2013; 81 (5): 410–416. DOI: 10.1212/WNL.0b013e31829d873c
  50. Lang Y., Gong D., Fan Y. Calcium channel blocker use and risk of Parkinson’s disease: a meta-analysis. Pharmacoepidemiol. Drug. Saf. 2015; 24 (6): 559–566. DOI: 10.1002/pds.3781
  51. Sheng Z., Jia X., Kang M. Statin use and risk of Parkinson’s disease: a meta-analysis. Behav. Brain.Res. 2016; 309: 29–34. DOI: 10.1016/j.bbr.2016.04.046
  52. Babar B.A., Kettunen R., Tiihonen M., Hartikainen S., Tolppanen A.M. Prevalence of cardiovascular drugs and oral anticoagulant use among persons with and without Parkinson’s disease. Cardiology. 2024; 149 (2): 127–136. DOI: 10.1159/000535691
  53. Rivasi G., Rafanelli M., Mossello E., Brignole M., Ungar A. Drug-related orthostatic hypotension: beyond anti-hypertensive medications. Drugs. Aging. 2020; 37 (10): 725–738. DOI: 10.1007/s40266-020-00796-5
  54. Wojtala J., Heber I.A., Neuser P., Heller J., Kalbe E., Rehberg S.P. et al. Cognitive decline in Parkinson’s disease: the impact of the motor phenotype on cognition. J. Neurol. Neurosurg. Psychiatry. 2019; 90 (2): 171–179. DOI: 10.1136/jnnp-2018-319008
  55. Mehrpouya M., Ataei S., Nili-Ahmadabadi A. Potential drug interactions with cholinesterase inhibitors in alzheimer patients: a guideline for neurologists. J. Appl. Pharm. Sci. 2017; 7 (1): 223–230. DOI: 10.7324/JAPS.2017.70134
  56. Chaumont M., Pourcelet A., Nuffelen M., Racapé J., Leeman M., Hougardy J.M. Acute kidney injury in elderly patients with chronic kidney disease: do angiotensin-converting enzyme inhibitors carry a risk? J. Clin. Hypertens. 2016; 18 (6): 514–521. DOI: 10.1111/jch.12795
  57. Lertxundi U., Domingo-Echaburu S., Soraluce A., García M., Ruiz-Osante B., Aguirre C. Domperidone in Parkinson’s disease: a perilous arrhythmogenic or the gold standard? Curr. Drug. Saf. 2013; 8: 63–68. DOI: 10.2174/1574886311308010009
  58. Simeonova M., Vries F., Pouwels S., Driessen J.H., Leufkens H.G., Cadarette S.M. et al. Increased risk of all‐cause mortality associated with domperidone use in Parkinson’s patients: a population‐based cohort study in the UK. Br. J. Clin. Pharmacol. 2018; 84 (11): 2551–2561. DOI: 10.1111/bcp.13708
  59. Günaydın Z.Y., Özer F.F., Karagöz A., Bektaş O., Karataş M.B., Vural A. et al. Evaluation of cardiovascular risk in patients with Parkinson disease under levodopa treatment. J. Geriatr. Cardiol. 2016; 13 (1): 75–80. DOI: 10.11909/j.issn.1671-5411.2016.01.003

 If you found mistakes, select text and press Alt+A